Nanjing, Jiangsu Province, China
- Featured
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Phase
2Span
227 weeksSponsor
Mirati Therapeutics Inc.Ostrava-Vitkovice
Recruiting
1-1 of 1